{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:36:33Z","timestamp":1787070993288,"version":"build-2736575974"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Luteinizing hormone-releasing hormone agonists, used in advanced prostate cancer, can cause an initial testosterone surge and may inadequately suppress follicle-stimulating hormone, potentially promoting tumor growth. Injectable gonadotropin-releasing hormone (GnRH) antagonists avoid this surge but have drawbacks like injection-site reactions and monthly dosing. Relugolix, an oral GnRH antagonist, offers rapid testosterone suppression without flare and reduced cardiovascular risks. We report a 72-year-old man with suspected metastatic prostate cancer, presenting with severe neuritic pain and lower limb weakness. Relugolix, started before biopsy along with zoledronic acid and steroids, led to symptom relief within 24 h. This case supports Relugolix\u2019s utility in urgent hormone-sensitive metastatic prostate cancer care.<\/jats:p>","DOI":"10.4103\/aam.aam_192_25","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T11:00:10Z","timestamp":1757415610000},"page":"948-950","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Relugolix for Metastatic Hormone-sensitive Prostate Cancer with Impending Paraplegia"],"prefix":"10.4103","volume":"25","author":[{"given":"Prem","family":"Kumar","sequence":"first","affiliation":[{"name":"Department of Urology, Ranchi Urology Centre, Ranchi, Jharkhand, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pragya","family":"Prem","sequence":"additional","affiliation":[{"name":"Department of Urology, Ranchi Urology Centre, Ranchi, Jharkhand, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raajul","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Radiodiagnosis, Samford Hospital, Ranchi, Jharkhand, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziaur","family":"Rahman","sequence":"additional","affiliation":[{"name":"Department of Pathology, Dr. Lal Path Labs, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"key":"R1-20260803","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.urology.2009.08.008","article-title":"Does oral antiandrogen use before leuteinizing hormone-releasing hormone therapy in patients with metastatic prostate cancer prevent clinical consequences of a testosterone flare?","volume":"75","author":"Oh","year":"2010","journal-title":"Urology"},{"key":"R2-20260803","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1146\/annurev.med.45.1.391","article-title":"Gonadotropin-releasing hormone and its analogs","volume":"45","author":"Conn","year":"1994","journal-title":"Annu Rev Med"},{"key":"R3-20260803","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1210\/jc.2015-2770","article-title":"Medical castration using the investigational oral GnRH antagonist TAK-385 (Relugolix): Phase 1 study in healthy males","volume":"100","author":"MacLean","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"R4-20260803","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.eururo.2020.03.001","article-title":"The oral gonadotropin-releasing hormone receptor antagonist relugolix as neoadjuvant\/adjuvant androgen deprivation therapy to external beam radiotherapy in patients with localised intermediate-risk prostate cancer: A randomised, open-label, parallel-group phase 2 trial","volume":"78","author":"Dearnaley","year":"2020","journal-title":"Eur Urol"},{"key":"R5-20260803","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral relugolix for androgen-deprivation therapy in advanced prostate cancer","volume":"382","author":"Shore","year":"2020","journal-title":"N Engl J Med"},{"key":"R6-20260803","first-page":"1364","article-title":"HERO: Relugolix versus leuprolide for advanced prostate cancer","volume":"39","author":"Crawford","year":"2021","journal-title":"J Clin Oncol"},{"key":"R7-20260803","first-page":"521.e1","article-title":"Comparative effectiveness of relugolix versus leuprolide in advanced prostate cancer","volume":"38","author":"Miller","year":"2020","journal-title":"Urol Oncol"},{"key":"R8-20260803","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1080\/2090598X.2021.1994231","article-title":"Relugolix: A new kid on the block among gonadotrophin-releasing hormone antagonists","volume":"19","author":"Fragkoulis","year":"2021","journal-title":"Arab J Urol"},{"key":"R9-20260803","first-page":"1601","article-title":"Anti-inflammatory effects of hormone suppression in cancer patients with bone metastases","volume":"13","author":"Simone","year":"2020","journal-title":"J Pain Res"},{"key":"R10-20260803","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3389\/fendo.2017.00187","article-title":"The role of gonadotropin-releasing hormone in cancer cell proliferation and metastasis","volume":"8","author":"Gr\u00fcndker","year":"2017","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Annals of African Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aam.aam_192_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:40:04Z","timestamp":1787067604000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aam.aam_192_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,9]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/aam.aam_192_25","relation":{},"ISSN":["1596-3519","0975-5764"],"issn-type":[{"value":"1596-3519","type":"print"},{"value":"0975-5764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,9]]},"assertion":[{"value":"2025-05-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}